JITSUBO Co., Ltd.

JITSUBO Co., Ltd. is a Japanese contract development and manufacturing organization (CDMO) specializing in peptides. Founded on 8 April 2005 and headquartered in Yokohama, Kanagawa, the company has built its business around a proprietary peptide synthesis platform it calls Molecular Hiving™. Rather than competing as a generic chemical manufacturer, JITSUBO positions itself as a technology-driven partner for pharmaceutical and biotechnology companies that need peptide active pharmaceutical ingredients (APIs) produced efficiently, at lower cost, and with a reduced environmental footprint. The company's service scope covers the full early-to-clinical chain: development of synthetic routes, process optimization, impurity synthesis, analytical method development for peptide drug substances, and contract synthesis of peptides ranging from research-stage samples up to investigational medicinal products. It also licenses its technology. According to its own account, JITSUBO has focused in recent years on shortening peptide elongation reaction times, using greener and safer raw materials, and minimizing the quantities of those materials — improvements aimed at making commercial-scale peptide production viable. JITSUBO is a small, privately held company. Its stated capital is 10 million yen and its workforce is around 15 people, which places it among the smaller specialized Japanese CDMOs. Despite its size, it has attracted international attention: its Molecular Hiving™ technology was presented at TIDES USA 2025, a major oligonucleotide and peptide therapeutics conference, and in June 2023 the company announced an exclusive manufacturing license agreement with Novo Nordisk in the fields of diabetes, obesity, and related diseases. That agreement is a significant validation of the platform, given Novo Nordisk's prominence in peptide-based metabolic medicines. Leadership is drawn from large Japanese pharmaceutical companies. Representative Director and President Hideya Mizufune, Ph.D., spent most of his career at Takeda Pharmaceutical Company, working on small-molecule API process development and CMC development, later serving as a research manager and director in global API process R&D, before moving to Spera Pharma as head of pharmaceutical research and then chief technology officer. He became president of JITSUBO in December 2021. Director Ichiro Shima, Ph.D., came from Fujisawa Pharmaceutical (later Astellas Pharma), worked as a medicinal chemist, and held senior research roles at JITSUBO before becoming a director in June 2023. The board also includes Keitaro Iwaki, president of Spera Pharma, and Keisuke Bando, sales manager at Spera Pharma, with Toshimitsu Isobe as auditor. The company frames its purpose in patient-centric terms: its vision is to "enrich the world with smile," its mission is to create technology that serves people's health over the long term and to turn invention and innovation into value for society, and its tagline is "Creating future smiles with peptides." JITSUBO's market is global in aspiration but rooted in Japan's pharmaceutical supply chain, and its competitive edge rests on the Molecular Hiving™ process rather than on scale.

JITSUBO Co., Ltd. was founded on 8 April 2005 in Japan. From its base in Yokohama, Kanagawa, the company concentrated on peptide chemistry, an area of pharmaceutical science that has grown in strategic importance as peptide-based medicines for metabolic disease, oncology, and other indications have expanded. Rather than pursuing broad chemical manufacturing, JITSUBO chose to develop a differentiated synthesis method, which it branded Molecular Hiving™. Over the years the company's stated technical focus shifted toward the requirements of commercial production. According to its own account, JITSUBO worked on shortening the time required for peptide elongation reactions, on using greener and safer raw materials, and on minimizing the amounts of those materials. The company describes these efforts as having matured into a manufacturing technology capable of producing high-quality peptide APIs at low cost while being environmentally friendly. This combination — cost, quality, and environmental profile — is the core of its pitch to pharmaceutical partners. A significant commercial milestone came on 15 June 2023, when JITSUBO announced an exclusive manufacturing license agreement with Novo Nordisk in the fields of diabetes, obesity, and related diseases. Novo Nordisk is a leading developer of peptide therapeutics in exactly those areas, so the agreement represented external validation of the Molecular Hiving™ platform. In April 2023 the company also announced it would exhibit at CPHI Japan 2023, reflecting an effort to raise its profile in the pharmaceutical ingredients and contract services market. Leadership has been drawn from established Japanese pharmaceutical companies. Hideya Mizufune, Ph.D., who spent much of his career at Takeda Pharmaceutical Company in API process and CMC development and later served as chief technology officer at Spera Pharma, became Representative Director and President of JITSUBO in December 2021. Ichiro Shima, Ph.D., a medicinal chemist who began his career at Fujisawa Pharmaceutical and later worked at Astellas Pharma, joined JITSUBO in 2017 and became a director in June 2023 after serving as principal researcher, head of R&D, and chief technology officer. The board also includes Keitaro Iwaki, president of Spera Pharma, as chairman, and Keisuke Bando, sales manager at Spera Pharma, as a director, with Toshimitsu Isobe as auditor. These ties suggest a close relationship with Spera Pharma, though JITSUBO is described as a private company with capital of 10 million yen and about 15 employees. In July 2025 the company announced that its Molecular Hiving™ technology had been introduced at TIDES USA 2025, an international conference focused on oligonucleotide and peptide therapeutics. The presentation marked another step in JITSUBO's effort to position itself internationally as a peptide technology and manufacturing specialist. The company continues to describe its purpose in patient-oriented terms, with the vision "Enrich the world with smile," the mission to create technology that serves people's health over the long term, and the tagline "Creating future smiles with peptides."

• JITSUBO Co., Ltd. founded in Japan.

• Ichiro Shima, Ph.D. joins JITSUBO; later serves as principal researcher, head of R&D, and chief technology officer.

• Hideya Mizufune, Ph.D. becomes Representative Director and President.

• Announcement of exhibition at CPHI Japan 2023.

• Exclusive manufacturing license agreement with Novo Nordisk in diabetes, obesity and related disease fields announced.

• Ichiro Shima, Ph.D. appointed director.

• Molecular Hiving™ technology introduced at TIDES USA 2025.

Technology-driven peptide CDMO offering cost-effective, environmentally friendly peptide API synthesis and licensing its proprietary Molecular Hiving™ platform.

• Molecular Hiving™ peptide synthesis technology

  Proprietary peptide synthesis method developed by JITSUBO, focused on shortening elongation reaction times and using greener, safer raw materials in minimized quantities.

• Contract peptide synthesis services

  Synthesis of peptides from research-stage samples to investigational drug substances, including process development, impurity synthesis, and analytical method development.

• Technology licensing

  Licensing of the Molecular Hiving™ platform, including an exclusive manufacturing license with Novo Nordisk announced in June 2023.

1. 1JITSUBO株式会社 | ペプチドで、未来の笑顔を創造しようjitsubo.com
2. 2企業紹介｜JITSUBO株式会社jitsubo.com
3. 3JITSUBO Co., Ltd. (Japan) - Wikidatawikidata.org